Holocene Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Holocene Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.15M	Sell	12,384 -55,234	-82%	-$24.5M	0.01%	378
2026 Q1	$30.2M	Buy	67,618 +66,140	+4,475%	+$30.8M	0.07%	232
2025 Q4	$670K	Buy	+1,478	New	+$637K	﹤0.01%	645
2025 Q3	–	Sell	-1,216	Closed	-$541K	–	922
2025 Q2	$541K	Hold	1,216	–	–	﹤0.01%	693
2025 Q1	$590K	Sell	1,216 -327	-21%	-$152K	﹤0.01%	664
2024 Q4	$621K	Buy	+1,543	New	+$715K	﹤0.01%	697
2022 Q3	–	Sell	-500,130	Closed	-$141M	–	971
2022 Q2	$141M	Buy	500,130 +359	+0.1%	+$96.1K	0.85%	31
2022 Q1	$130M	Buy	+499,771	New	+$119M	0.68%	44
2021 Q3	–	Sell	-2,693	Closed	-$543K	–	981
2021 Q2	$543K	Sell	2,693 -3,078	-53%	-$644K	﹤0.01%	730
2021 Q1	$1.24M	Buy	5,771 +1,997	+53%	+$439K	0.01%	669
2020 Q4	$892K	Buy	+3,774	New	+$866K	0.01%	565
2020 Q3	–	Sell	-118,153	Closed	-$34.3M	–	800
2020 Q2	$34.3M	Sell	118,153 -318,634	-73%	-$86.4M	0.3%	101
2020 Q1	$104M	Sell	436,787 -66,148	-13%	-$15.2M	1.12%	26
2019 Q4	$110M	Buy	502,935 +64,252	+15%	+$13M	0.99%	25
2019 Q3	$74.3M	Buy	+438,683	New	+$77.6M	0.77%	40
2018 Q2	–	Sell	-1,346	Closed	-$219K	–	747
2018 Q1	$219K	Buy	+1,346	New	+$220K	﹤0.01%	499

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Holocene Advisors's VRTX Position: Q2 2026 in Review

Holocene Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 82% in Q2 2026, selling an estimated $24.5M and leaving 12,384 shares worth $6.15M. The position accounts for 0.01% of the portfolio, ranked #378.

Holocene Advisors first reported a position in VRTX in Q1 2018 and has held it in 16 quarters since. The position peaked at $141M in Q2 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Holocene Advisors held 12,384 shares of Vertex Pharmaceuticals worth $6.15M as of Q2 2026.
Holocene Advisors sold 55,234 Vertex Pharmaceuticals shares in Q2 2026, an estimated $24.5M.
Vertex Pharmaceuticals made up 0.01% of Holocene Advisors's portfolio in Q2 2026, its #378 holding.
Holocene Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 16 quarters since.
Holocene Advisors's Vertex Pharmaceuticals position peaked at $141M in Q2 2022.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.